Randomized trials show PCSK9 inhibitors added to statin therapy reduce major cardiovascular events
3 events · 1 assessment · 1 decision
Structured and assessed
First pass. Kept the claim atomic: probing the Matcher with per-trial formulations (FOURIER/evolocumab, ODYSSEY OUTCOMES/alirocumab) returned the class-level claim 49d3bfd6 rather than this node, so minting trial-specific subclaims would have created duplicates; the trial specifics are carried in the assessment prose instead. Canonical form left unchanged (neutral, ~14 words). Set importance 0.35 / contestation 0.1 (notable evidentiary claim, settled). Assessed verified (confidence 0.95, credence 0.97) on direct trial evidence: FOURIER HR 0.85 (0.79-0.92) and ODYSSEY OUTCOMES HR ~0.85, both on statin backgrounds, no retractions. Surrounding debates (absolute magnitude, mortality benefit, cost-effectiveness, the FOURIER mortality re-analysis) concern claims this node does not assert and were judged non-material. Noted but did not escalate the close similarity to parent 49d3bfd6: the two are used distinctly (this node is the direct-trial-evidence line within the parent's for-argument), so the current structure is coherent.
Assessed Verified
verdict confidence 0.95 · credence 0.97
Two large, double-blind, placebo-controlled outcome trials establish this directly. In FOURIER, evolocumab added to statin therapy in 27,564 patients with stable atherosclerotic disease reduced the primary composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, with a hazard ratio of 0.85 (95% CI 0.79 to 0.92) over a median 2.2 years. In ODYSSEY OUTCOMES, alirocumab added to high-intensity or maximally tolerated statins after a recent acute coronary syndrome reduced major adverse cardiovascular events by the same hazard ratio of about 0.85. Both trials enrolled statin-treated patients, so they test precisely the incremental benefit of adding a PCSK9 inhibitor. The result is consistent across trials, drugs, and prespecified subgroups, and it aligns with the broader finding that lowering LDL cholesterol reduces cardiovascular events roughly in proportion to the reduction achieved. The finding is not seriously contested. Debate around these agents concerns matters this claim does not assert: the absolute risk reductions were modest (on the order of 1.5 to 2 percent over a few years), neither trial demonstrated a robust reduction in all-cause or cardiovascular mortality, and cost-effectiveness against generic statins and ezetimibe remains argued. A re-analysis of FOURIER mortality data has also circulated, but it bears on the mortality question, not on the reduction of the composite event endpoint. What would overturn the claim, a large trial showing no event reduction or retraction of the pivotal trials, has not occurred.
Claim entered the graph